FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
A new dawn for tovorafenib
The FDA's tough stance notwithstanding, Ojemda gets an accelerated green light.
GenFleet bids to join the colorectal KRAS crowd
Competitors have given up on monotherapies in this use, but GenFleet wants to buck the trend.
